Epstein-barr virus vaccination of transplant candidates: light at the end of the tunnel?
Allen
Upton D
UD
Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. upton.allen@sickkids.ca
D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000276:immunology* / Q000517:prevention & control; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008562:Membrane Glycoproteins / Q000276:immunology*; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control; D021122:Protein Subunits / Q000276:immunology; D014181:Transplantation Immunology; D014763:Viral Matrix Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000627:therapeutic use*
C034059:GP 300-350, Epstein-Barr virus; D008562:Membrane Glycoproteins; D021122:Protein Subunits; D014763:Viral Matrix Proteins; D014765:Viral Vaccines